Strategic Partnerships Small team size and ongoing capital challenges make Oncorus a strong candidate for strategic collaborations or licensing deals with larger pharmaceutical partners to advance their IV-administered self-amplifying RNA cancer therapies without heavy internal expansion.

Outsourced Development Their likely reliance on CROs and CMOs for R&D and clinical execution creates immediate sales opportunities for viral immunotherapy focused CROs, manufacturing partners, and clinical logistics providers who can offer scale without long internal headcount.

Capital Partnerships Funding volatility signals potential for strategic financing partnerships, non-dilutive funding options, and investor relations support from banks or venture funds specializing in oncology biotech to help de-risk development milestones.

IR Support Active participation in investor conferences combined with stock volatility indicates a need for polished IR and communications services to clarify value proposition, attract partners, and accelerate deal discussions.

Competitive Positioning Competitive positioning and market intelligence could help Oncorus differentiate its self-amplifying RNA approach in the crowded cancer immunotherapy space, guiding partner targeting, messaging, and deal structuring.